Please select the option that best describes you:
How would you sequence SRS for brain metastases for a patient receiving dual immunotherapies?
Is there an optimal time to give SRS to brain metastases for patients receiving ipilimumab and nivolumab?
Answer from: Radiation Oncologist at Academic Institution
To be honest the strategy in this regard at our center has been haphazard at best. I have not seen any adverse effects that could be clearly related to concurrence of combination dual immunotherapy therapy and GK SRS.My colleague Marc Ernstoff reported results of the Checkmate study which clearly po...
Sign in or Register to read more